RESMED/IDR UNRESTR (ASX:RMD) Stock Price Crosses Above Fifty Day Moving Average of $21.35

RESMED/IDR UNRESTR (ASX:RMD) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $21.35 and traded as high as $22.01. RESMED/IDR UNRESTR shares last traded at $21.87, with a volume of 398,206 shares trading hands.

The company has a market cap of $31.53 billion and a P/E ratio of 75.62. The company has a current ratio of 2.11, a quick ratio of 1.23 and a debt-to-equity ratio of 61.66. The firm’s 50 day moving average price is A$21.48 and its 200-day moving average price is A$18.95.

The firm also recently announced a interim dividend, which was paid on Thursday, December 12th. Stockholders of record on Thursday, December 12th were paid a $0.04 dividend. This represents a dividend yield of 0.19%. The ex-dividend date was Wednesday, November 6th. This is a positive change from RESMED/IDR UNRESTR’s previous interim dividend of $0.04. RESMED/IDR UNRESTR’s dividend payout ratio (DPR) is 79.31%.

About RESMED/IDR UNRESTR (ASX:RMD)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Further Reading: Net Margin – Understanding the Different Kinds of Profit

Receive News & Ratings for RESMED/IDR UNRESTR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RESMED/IDR UNRESTR and related companies with MarketBeat.com's FREE daily email newsletter.